Dimethyl succinate

Dimethyl succinate is an orally active cell permeable succinate analogue. Dimethyl succinate can disrupt the TCA cycle by elevating intracellular succinate levels, leading to reduced protein synthesis and impairs myogenic differentiation. Dimethyl succinate can induce apoptosis. Dimethyl succinate can decrease maximal cellular respiration and reserve capacity. Dimethyl succinate can rescue synapse loss in AD. Dimethyl succinate can be used for the researches of metabolic and neurological disease^[1][2]. In Vitro:Dimethyl succinate (16 mM) increases apoptotic cells in C2C12 myoblasts^[1].
Dimethyl succinate (4-8 mM, 48 h) increases intracellular succinate, malate and glutamate in C2C12 myoblasts^[1]. Dimethyl succinate (8 mM, 48 h) reduces protein anabolism as determined by an O-propargyl-puromycin (OPP) incorporation assay in C2C12 myoblasts^[1]. Dimethyl succinate (8 mM) reduces maximal respiration and mitochondria reserve capacity in C2C12 myoblasts^[1]. Dimethyl succinate (8 mM) results in an impaired ability to form mature, multinucleated Myosin Heavy Chain-positive structures in C2C12 myoblasts^[1]. Dimethyl succinate (5 mM, 48 h) partially rescues synapse loss in AD hiPSC-derived cerebrocortical neurons^[2]. In Vivo:Dimethyl succinate (2% in water, p.o., 6 weeks) impairs skeletal muscle homeostasis and regeneration, leading to smaller muscle myofiber diameters^[1].